NASDAQ, CPRX - Catalyst Pharm Inc
We are a biopharmaceutical company focused on the development and
commercialization of prescription drugs for the treatment of addiction. Our
initial product candidate is CPP-109, which is our version of the chemical
compound gamma-vinyl-GABA, commonly referred to as vigabatrin. We are currently
conducting a clinical study of CPP-109 for use in the treatment of cocaine
addiction, and we intend to conduct clinical studies of CPP-109 for use in the
treatment of methamphetamine addiction. We also believe that CPP-109 has the
potential to treat other addictions, including addictions to nicotine,
prescription pain medications, alcohol, and marijuana, as well as
obsessive-compulsive disorders such as obesity and compulsive gambling. We
intend to develop CPP-109 to treat other forms of addiction, such as those
described above, subject to the availability of funding for such purposes.
We have initiated a randomized, double-blind, placebo-controlled U.S. ...
Read SEC Filing on NASDAQ.com »